相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Effects of rich cannabidiol oil on behavioral disturbances in patients with dementia: A placebo controlled randomized clinical trial
Vered Hermush et al.
FRONTIERS IN MEDICINE (2022)
Cannabidiol, but Not Δ9-Tetrahydrocannabinol, Has Strain- and Genotype-Specific Effects in Models of Psychosis
Catharine A. Mielnik et al.
CANNABIS AND CANNABINOID RESEARCH (2022)
Pre-pulse inhibition deficits in individuals at clinical high-risk for psychosis: A systematic review and meta-analysis
Weidi Li et al.
EARLY INTERVENTION IN PSYCHIATRY (2021)
Cannabidiol and Amisulpride Improve Cognition in Acute Schizophrenia in an Explorative, Double-Blind, Active-Controlled, Randomized Clinical Trial
F. Markus Leweke et al.
FRONTIERS IN PHARMACOLOGY (2021)
Approved cannabinoids for medical purposes-Comparative systematic review and meta-analysis for sleep and appetite
Rainer Spanagel et al.
NEUROPHARMACOLOGY (2021)
Metabolic abnormalities and low dietary Omega 3 are associated with symptom severity and worse functioning prior to the onset of psychosis: Findings from the North American Prodrome Longitudinal Studies Consortium
Kristin S. Cadenhead et al.
SCHIZOPHRENIA RESEARCH (2019)
The behavioral effects of CBD and THC in mouse models of psychosis
C.K. Li et al.
CLINICAL NEUROPHYSIOLOGY (2019)
Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial
Philip McGuire et al.
AMERICAN JOURNAL OF PSYCHIATRY (2018)
Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome
Orrin Devinsky et al.
NEUROLOGY (2018)
The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial
Douglas L. Boggs et al.
PSYCHOPHARMACOLOGY (2018)
Inflammation in Schizophrenia: Pathogenetic Aspects and Therapeutic Considerations
Norbert Mueller
SCHIZOPHRENIA BULLETIN (2018)
Pharmacological properties of cannabidiol in the treatment of psychiatric disorders: a critical overview
G. M. Mandolini et al.
EPIDEMIOLOGY AND PSYCHIATRIC SCIENCES (2018)
Effect of Cannabidiol on Medial Temporal, Midbrain, and Striatal Dysfunction in People at Clinical High Risk of Psychosis A Randomized Clinical Trial
Sagnik Bhattacharyya et al.
JAMA PSYCHIATRY (2018)
Cannabidiol Administered During Peri-Adolescence Prevents Behavioral Abnormalities in an Animal Model of Schizophrenia
Fernanda F. Peres et al.
FRONTIERS IN PHARMACOLOGY (2018)
Seeing through the smoke: Human and animal studies of cannabis use and endocannabinoid signalling in corticolimbic networks
Mason M. Silveira et al.
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS (2017)
A systematic review of the effect of cannabidiol on cognitive function: Relevance to schizophrenia
Ashleigh L. Osborne et al.
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS (2017)
Cannabidiol reduces neuroinflammation and promotes neuroplasticity and functional recovery after brain ischemia
Marco Aurelio Mori et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2017)
Cannabidiol (CBD) induces functional Tregs in response to low-level T cell activation
Saphala Dhital et al.
CELLULAR IMMUNOLOGY (2017)
Cannabinoids and Cytochrome P450 Interactions
Ondrej Zendulka et al.
CURRENT DRUG METABOLISM (2016)
Cannabidiol (CBD) and its analogs: a review of their effects on inflammation
Sumner Burstein
BIOORGANIC & MEDICINAL CHEMISTRY (2015)
Towards a Psychosis Risk Blood Diagnostic for Persons Experiencing High-Risk Symptoms: Preliminary Results From the NAPLS Project
Diana O. Perkins et al.
SCHIZOPHRENIA BULLETIN (2015)
Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review
Stephen M. Stout et al.
DRUG METABOLISM REVIEWS (2014)
Efficacy of Anti-inflammatory Agents to Improve Symptoms in Patients With Schizophrenia: An Update
Iris E. Sommer et al.
SCHIZOPHRENIA BULLETIN (2014)
Cardiometabolic Risk in Patients With First-Episode Schizophrenia Spectrum Disorders Baseline Results From the RAISE-ETP Study
Christoph U. Correll et al.
JAMA PSYCHIATRY (2014)
Cannabidiol inhibits the reward-facilitating effect of morphine: involvement of 5-HT1A receptors in the dorsal raphe nucleus
Vicky Katsidoni et al.
ADDICTION BIOLOGY (2013)
Diagnostic and Statistical Manual of Mental Disorders, 5th Edition, and Clinical Utility
Michael B. First
JOURNAL OF NERVOUS AND MENTAL DISEASE (2013)
Endocannabinoid system: Potential novel targets for treatment of schizophrenia
Atsushi Saito et al.
NEUROBIOLOGY OF DISEASE (2013)
AGE OF STRESS EXPOSURE MODULATES THE IMMEDIATE AND SUSTAINED EFFECTS OF REPEATED STRESS ON CORTICOLIMBIC CANNABINOID CB1 RECEPTOR BINDING IN MALE RATS
T. T. Y. Lee et al.
NEUROSCIENCE (2013)
Developmental neuroinflammation and schizophrenia
Urs Meyer
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2013)
Adjunctive Use of Nonsteroidal Anti-inflammatory Drugs for Schizophrenia: A Meta-analytic Investigation of Randomized Controlled Trials
Masahiro Nitta et al.
SCHIZOPHRENIA BULLETIN (2013)
C-reactive protein is elevated in schizophrenia
Faith Dickerson et al.
SCHIZOPHRENIA RESEARCH (2013)
The Psychosis High-Risk State A Comprehensive State-of-the-Art Review
Paolo Fusar-Poli et al.
JAMA PSYCHIATRY (2013)
A Critical Review of the Antipsychotic Effects of Cannabidiol: 30 Years of a Translational Investigation
Antonio Waldo Zuardi et al.
CURRENT PHARMACEUTICAL DESIGN (2012)
Automatic sensory information processing abnormalities across the illness course of schizophrenia
C. Jahshan et al.
PSYCHOLOGICAL MEDICINE (2012)
Increased level of serum cytokines, chemokines and adipokines in patients with schizophrenia is associated with disease and metabolic syndrome
Wouter Beumer et al.
PSYCHONEUROENDOCRINOLOGY (2012)
Cannabinol and cannabidiol exert opposing effects on rat feeding patterns
Jonathan A. Farrimond et al.
PSYCHOPHARMACOLOGY (2012)
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
F. M. Leweke et al.
TRANSLATIONAL PSYCHIATRY (2012)
The Columbia-Suicide Severity Rating Scale: Initial Validity and Internal Consistency Findings From Three Multisite Studies With Adolescents and Adults
Kelly Posner et al.
AMERICAN JOURNAL OF PSYCHIATRY (2011)
Meta-Analysis of Cytokine Alterations in Schizophrenia: Clinical Status and Antipsychotic Effects
Brian J. Miller et al.
BIOLOGICAL PSYCHIATRY (2011)
Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress
George W. Booz
FREE RADICAL BIOLOGY AND MEDICINE (2011)
Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naive Social Phobia Patients
Mateus M. Bergamaschi et al.
NEUROPSYCHOPHARMACOLOGY (2011)
Cannabidiol inhibits the hyperphagia induced by cannabinoid-1 or serotonin-1A receptor agonists
America A. Scopinho et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2011)
The interplay of cannabinoid and NMDA glutamate receptor systems in humans: Preliminary evidence of interactive effects of cannabidiol and ketamine in healthy human subjects
Jaime E. C. Hallak et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2011)
Differential Effects of Stress on [C-11]Raclopride and [C-11] MNPA Binding to Striatal D-2/D-3 Dopamine Receptors: A PET Study in Conscious Monkeys
Hideo Tsukada et al.
SYNAPSE (2011)
Differential Developmental Trajectories for CB1 Cannabinoid Receptor Expression in Limbic/Associative and Sensorimotor Cortical Areas
Lijun Heng et al.
SYNAPSE (2011)
Adjuvant Aspirin Therapy Reduces Symptoms of Schizophrenia Spectrum Disorders: Results From a Randomized, Double-Blind, Placebo-Controlled Trial
Wijnand Laan et al.
JOURNAL OF CLINICAL PSYCHIATRY (2010)
Course of Neurocognitive Deficits in the Prodrorne and First Episode of Schizophrenia
Carol Jahshan et al.
NEUROPSYCHOLOGY (2010)
Performance of schizophrenic patients in the Stroop Color Word Test and electrodermal responsiveness after acute administration of cannabidiol (CBD)
Jaime E. C. Hallak et al.
REVISTA BRASILEIRA DE PSIQUIATRIA (2010)
Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists
Patrik Roser et al.
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY (2010)
Longitudinal Changes in Cortisol Secretion and Conversion to Psychosis in At-Risk Youth
Elaine F. Walker et al.
JOURNAL OF ABNORMAL PSYCHOLOGY (2010)
Cannabidiol for the treatment of psychosis in Parkinson's disease
A. W. Zuardi et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2009)
The endocannabinoid system as a target for modelling psychosis
Dagmar Koethe et al.
PSYCHOPHARMACOLOGY (2009)
Epigenetic Mediation of Environmental Influences in Major Psychotic Disorders
Bart P. F. Rutten et al.
SCHIZOPHRENIA BULLETIN (2009)
Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb
Angelo A. Izzo et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2009)
Stress and the Hypothalamic Pituitary Adrenal Axis in the Developmental Course of Schizophrenia
Elaine Walker et al.
Annual Review of Clinical Psychology (2008)
Dynamic changes of the endogenous cannabinoid and opioid mesocorticolimbic systems during adolescence: THC effects
M. Ellgren et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2008)
Cannabinoid receptors: Where they are and what they do
K. Mackie
JOURNAL OF NEUROENDOCRINOLOGY (2008)
Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS)
Richard S. E. Keefe et al.
SCHIZOPHRENIA RESEARCH (2008)
The hallucinogenic herb Salvia divinorum and its active ingredient salvinorin A reduce inflammation-induced hypermotility in mice
R. Capasso et al.
NEUROGASTROENTEROLOGY AND MOTILITY (2008)
Acute effects of Δ9-tetrahydrocannabinol and standardized cannabis extract on the auditory evoked mismatch negativity
Georg Juckel et al.
SCHIZOPHRENIA RESEARCH (2007)
Association of amphetamine-induced striatal dopamine release and cortisol responses to psychological stress
Gary S. Wand et al.
NEUROPSYCHOPHARMACOLOGY (2007)
Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients:: Impact of cannabis use
F. Markus Leweke et al.
SCHIZOPHRENIA RESEARCH (2007)
Demographically corrected norms for the Brief Visuospatial Memory Test-revised and Hopkins Verbal Learning Test-revised in monolingual Spanish speakers from the US-Mexico border region
M. Cherner et al.
ARCHIVES OF CLINICAL NEUROPSYCHOLOGY (2007)
Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease:: Importance of antioxidant and cannabinoid receptor-independent properties
Moises Garcia-Arencibia et al.
BRAIN RESEARCH (2007)
Inhibition of an equilibrative nucleoside transporter by cannabidiol: A mechanism of cannabinoid immunosuppression
Erica J. Carrier et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
The schizophrenia cognition rating scale: An interview-based assessment and its relationship to cognition, real-world functioning, and functional capacity
RSE Keefe et al.
AMERICAN JOURNAL OF PSYCHIATRY (2006)
A tale of two cannabinoids: The therapeutic rationale for combining tetrahydrocannabinol and cannabidiol
E Russo et al.
MEDICAL HYPOTHESES (2006)
The endocannabinoid system as an emerging target of pharmacotherapy
Pal Pacher et al.
PHARMACOLOGICAL REVIEWS (2006)
Role of glucocorticoids in dopamine-related neuropsychiatric disorders
K Van Craenenbroeck et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2005)
Agonistic properties of cannabidiol at 5-HT1a receptors
EB Russo et al.
NEUROCHEMICAL RESEARCH (2005)
Paternal age and intelligence: implications for age-related genomic changes in male germ cells
D Malaspina et al.
PSYCHIATRIC GENETICS (2005)
Mismatch negativity deficits are associated with poor functioning in schizophrenia patients
GA Light et al.
ARCHIVES OF GENERAL PSYCHIATRY (2005)
A summary of the FDA-NIMH-MATRICS Workshop on Clinical Trial Design for Neurocognitive Drugs for Schizophrenia.
RW Buchanan et al.
SCHIZOPHRENIA BULLETIN (2005)
Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms
A Giuffrida et al.
NEUROPSYCHOPHARMACOLOGY (2004)
Endogenous cannabinoid system as a modulator of food intake
D Cota et al.
INTERNATIONAL JOURNAL OF OBESITY (2003)
The stress cascade and schizophrenia: Etiology and onset
C Corcoran et al.
SCHIZOPHRENIA BULLETIN (2003)
Cannabidiol: an overview of some chemical and pharmacological aspects. Part I: chemical aspects
R Mechoulam et al.
CHEMISTRY AND PHYSICS OF LIPIDS (2002)
Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study
L Arseneault et al.
BRITISH MEDICAL JOURNAL (2002)
Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide
T Bisogno et al.
BRITISH JOURNAL OF PHARMACOLOGY (2001)
Modulation of the startle response and startle laterality in relatives of schizophrenic patients and in subjects with schizotypal personality disorder: Evidence of inhibitory deficits
KS Cadenhead et al.
AMERICAN JOURNAL OF PSYCHIATRY (2000)
分享论文
